市場調査レポート

商品コード

1446916

神経芽細胞腫治療薬市場：タイプ別、投与経路別、流通チャネル別：世界の機会分析と産業予測、2023-2032年

Neuroblastoma Drugs Market By Type (Chemotherapy, Immunotherapy, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Online, Offline): Global Opportunity Analysis and Industry Forecast, 2023-2032

出版日: 2024年01月30日 | 発行: Allied Market Research

| ページ情報: 英文 256 Pages | 納期: 2～3営業日

価格

Cloud Access (Single User License)

USD 3,570 562,382円

レポートのクラウドアクセスでご利用頂けるライセンスです。ウェブポータルで配信され、60日間レポートにアクセスできます。この期間を過ぎるとレポートへのアクセスは失効します。コンテンツのダウンロード、印刷、共有、コピー＆ペーストはできません。

PDF (Business License)

USD 5,730 902,646円

レポートPDFをご利用いただけるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDFl内のテキスト等のコピー＆ペーストは可能です。印刷は5回可能です。追加料金を支払うことで、2～5ユーザーを収容できるようにアップグレードできます。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,512,288円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.53円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

神経芽細胞腫治療薬市場は、2022年には7億米ドルと評価され、2023年から2032年までのCAGRは6.2％を示し、2032年には13億米ドルに達すると推定されています。

神経芽細胞腫は、主に幼児に発症するがんの一種で、通常は腎臓の上部にある副腎に発生します。5歳未満の小児で最も多く診断される疾患で、ほとんどの症例が乳幼児に現れます。このがんは神経芽細胞と呼ばれる未熟な神経細胞から発生し、神経芽細胞は闘争・逃走反応を司る交感神経系の一部です。

神経芽細胞腫は、自然に退行または成熟するものから、攻撃的で急速に拡大するものまで、その挙動が大きく異なります。神経芽細胞腫の症状は腫瘍の位置や大きさによって異なるが、腹部の腫脹、体重減少、過敏性、疲労、および腸の習慣の変化などがあります。神経芽細胞腫治療薬は、がん細胞を直接攻撃するか、または腫瘍の発生に関与する生物学的経路を調節することによって、がん化した神経芽腫細胞を標的として増殖を抑制するように設計されています。神経芽腫の治療法には、手術、化学療法、放射線療法、免疫療法、その他の標的療法が組み合わされることが多いです。

神経芽細胞腫治療薬市場は、神経芽腫の発生率の上昇、研究開発活動の進展、神経芽腫に対する認識の高まりによって牽引されています。特に小児集団における神経芽腫の発生率と有病率の増加は、神経芽細胞腫治療薬市場の成長を促進する極めて重要な要因です。例えば、2023年の米国生物工学情報センター（NCBI）によると、米国における神経芽細胞腫の年間発生率は約650例、すなわち小児100万人当たり10.2人でした。したがって、神経芽腫の有病率の増加は、市場成長に寄与する効果的で標的化された薬物療法の緊急の必要性につながった。

その結果、製薬会社や研究機関は、この健康上の懸念の高まりに対処するため、医薬品開発、臨床試験、共同研究イニシアティブへの取り組みを強化せざるを得なくなっています。疾病負担の増加に対する市場の反応は、神経芽腫に罹患した患者の転帰と生活の質を改善するための革新的な治療法を進歩させることの重要性を強調しています。さらに、製薬業界は腫瘍学の研究と医薬品開発に多額の投資を行っており、市場の成長を後押ししています。神経芽腫は、小児腫瘍学のサブセットとして、この広範な動向の恩恵を受けており、新規薬剤の発見と開発に割り当てられる資金と資源が増加しています。例えば、米国国立がん研究所（NCI）は基礎研究に多額の投資を行い、神経芽腫の治療薬ジヌツキシマブの開発につながった。

しかし、神経芽腫治療の高額な費用や神経芽細胞腫治療薬に関連する有害な副作用が、神経芽細胞腫治療薬市場の成長を阻害する要因となっています。対照的に、神経芽腫のパイプライン薬剤の増加は、市場成長に有利な機会を提供します。さらに、従来の化学療法薬、標的薬剤、免疫療法薬など、異なるクラスの薬剤を含む併用療法の探求は、治療効果を高める機会を提供しています。

利害関係者にとっての主なメリット

当レポートは、2022年から2032年までの神経芽細胞腫治療薬市場分析の市場セグメント、現在の動向、推定・力学の定量分析を提供し、優勢な神経芽細胞腫治療薬市場機会を特定します。
市場促進要因、市場抑制要因、市場機会に関連する情報とともに市場調査を提供します。
ポーターのファイブフォース分析では、利害関係者が利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるよう、バイヤーとサプライヤーの潜在力を明らかにします。
神経芽細胞腫治療薬市場のセグメンテーションの詳細な分析は、市場機会を決定するのに役立ちます。
各地域の主要国は、世界市場への収益貢献度に応じてマッピングされています。
市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
本レポートには、地域別および世界の神経芽細胞腫治療薬市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析が含まれています。

本レポートはカスタマイズが可能です。

規制ガイドライン
顧客の関心に応じた企業プロファイルの追加
国別または地域別の追加分析-市場規模と予測
企業プロファイルの拡張リスト
過去の市場データ
主要プレーヤーの詳細（所在地、連絡先、サプライヤー／ベンダーネットワークなどを含む、エクセル形式）

市場の定義と範囲
主な調査結果
- 影響要因
- 主な投資機会
ポーターのファイブフォース分析
市場力学
- 促進要因
  - 神経芽腫の有病率の上昇
  - 神経芽腫に対する政府の認識およびイニシアチブの高まり
  - 研究開発活動の増加
- 抑制要因
  - 副作用と安全性への懸念
- 機会
  - 新興市場における成長機会
  - パイプライン製品の増加

第4章神経芽細胞腫治療薬市場：タイプ別

概要
化学療法
免疫療法
その他

第5章神経芽細胞腫治療薬市場：投与経路別

概要
経口剤
注射剤

第6章神経芽細胞腫治療薬市場：流通チャネル別

概要
オンライン
オフライン

第7章神経芽細胞腫治療薬市場：地域別

概要
北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- その他
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- 韓国
- その他
ラテンアメリカ・中東・アフリカ
- ブラジル
- サウジアラビア
- 南アフリカ
- その他

第8章競争情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合ヒートマップ
主要企業のポジショニング、2022年

第9章企業プロファイル

Recordati Group
AstraZeneca plc
Bristol-Myers Squibb Company
Cellectar Biosciences, Inc.
Eli Lilly and Company
MacroGenics Inc.
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
United Therapeutics Corporation
Y-mabs Therapeutics, Inc.

図表

LIST OF TABLES

TABLE 01. GLOBAL NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 02. NEUROBLASTOMA DRUGS MARKET FOR CHEMOTHERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 03. NEUROBLASTOMA DRUGS MARKET FOR IMMUNOTHERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 04. NEUROBLASTOMA DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 06. NEUROBLASTOMA DRUGS MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
TABLE 07. NEUROBLASTOMA DRUGS MARKET FOR INJECTABLE, BY REGION, 2022-2032 ($MILLION)
TABLE 08. GLOBAL NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 09. NEUROBLASTOMA DRUGS MARKET FOR ONLINE, BY REGION, 2022-2032 ($MILLION)
TABLE 10. NEUROBLASTOMA DRUGS MARKET FOR OFFLINE, BY REGION, 2022-2032 ($MILLION)
TABLE 11. NEUROBLASTOMA DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 12. NORTH AMERICA NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 13. NORTH AMERICA NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA NEUROBLASTOMA DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 16. U.S. NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 17. U.S. NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 18. U.S. NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 19. CANADA NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 20. CANADA NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 21. CANADA NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 22. MEXICO NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 23. MEXICO NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 24. MEXICO NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 25. EUROPE NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 26. EUROPE NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 27. EUROPE NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 28. EUROPE NEUROBLASTOMA DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 29. GERMANY NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 30. GERMANY NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 31. GERMANY NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 32. FRANCE NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 33. FRANCE NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 34. FRANCE NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 35. UK NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 36. UK NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 37. UK NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 38. ITALY NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 39. ITALY NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 40. ITALY NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 41. SPAIN NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 42. SPAIN NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 43. SPAIN NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 44. REST OF EUROPE NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 45. REST OF EUROPE NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 46. REST OF EUROPE NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 47. ASIA-PACIFIC NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 48. ASIA-PACIFIC NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 49. ASIA-PACIFIC NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC NEUROBLASTOMA DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 51. JAPAN NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 52. JAPAN NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 53. JAPAN NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 54. CHINA NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 55. CHINA NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 56. CHINA NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 57. INDIA NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 58. INDIA NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 59. INDIA NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 60. AUSTRALIA NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 61. AUSTRALIA NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 62. AUSTRALIA NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 63. SOUTH KOREA NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 64. SOUTH KOREA NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 65. SOUTH KOREA NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 66. REST OF ASIA-PACIFIC NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 67. REST OF ASIA-PACIFIC NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 69. LAMEA NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 70. LAMEA NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 71. LAMEA NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 72. LAMEA NEUROBLASTOMA DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 73. BRAZIL NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 74. BRAZIL NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 75. BRAZIL NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 76. SAUDI ARABIA NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 77. SAUDI ARABIA NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 78. SAUDI ARABIA NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 79. SOUTH AFRICA NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 80. SOUTH AFRICA NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 81. SOUTH AFRICA NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 82. REST OF LAMEA NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 83. REST OF LAMEA NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 84. REST OF LAMEA NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 85. RECORDATI GROUP: KEY EXECUTIVES
TABLE 86. RECORDATI GROUP: COMPANY SNAPSHOT
TABLE 87. RECORDATI GROUP: PRODUCT SEGMENTS
TABLE 88. RECORDATI GROUP: PRODUCT PORTFOLIO
TABLE 89. RECORDATI GROUP: KEY STRATERGIES
TABLE 90. ASTRAZENECA PLC: KEY EXECUTIVES
TABLE 91. ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 92. ASTRAZENECA PLC: PRODUCT SEGMENTS
TABLE 93. ASTRAZENECA PLC: PRODUCT PORTFOLIO
TABLE 94. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
TABLE 95. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 96. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
TABLE 97. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 98. CELLECTAR BIOSCIENCES, INC.: KEY EXECUTIVES
TABLE 99. CELLECTAR BIOSCIENCES, INC.: COMPANY SNAPSHOT
TABLE 100. CELLECTAR BIOSCIENCES, INC.: PRODUCT SEGMENTS
TABLE 101. CELLECTAR BIOSCIENCES, INC.: PRODUCT PORTFOLIO
TABLE 102. ELI LILLY AND COMPANY: KEY EXECUTIVES
TABLE 103. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 104. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
TABLE 105. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 106. MACROGENICS INC.: KEY EXECUTIVES
TABLE 107. MACROGENICS INC.: COMPANY SNAPSHOT
TABLE 108. MACROGENICS INC.: PRODUCT SEGMENTS
TABLE 109. MACROGENICS INC.: PRODUCT PORTFOLIO
TABLE 110. PFIZER INC.: KEY EXECUTIVES
TABLE 111. PFIZER INC.: COMPANY SNAPSHOT
TABLE 112. PFIZER INC.: PRODUCT SEGMENTS
TABLE 113. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 114. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 115. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 116. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 117. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 118. UNITED THERAPEUTICS CORPORATION: KEY EXECUTIVES
TABLE 119. UNITED THERAPEUTICS CORPORATION: COMPANY SNAPSHOT
TABLE 120. UNITED THERAPEUTICS CORPORATION: PRODUCT SEGMENTS
TABLE 121. UNITED THERAPEUTICS CORPORATION: PRODUCT PORTFOLIO
TABLE 122. UNITED THERAPEUTICS CORPORATION: KEY STRATERGIES
TABLE 123. Y-MABS THERAPEUTICS, INC.: KEY EXECUTIVES
TABLE 124. Y-MABS THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 125. Y-MABS THERAPEUTICS, INC.: PRODUCT SEGMENTS
TABLE 126. Y-MABS THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 127. Y-MABS THERAPEUTICS, INC.: KEY STRATERGIES

LIST OF FIGURES

FIGURE 01. NEUROBLASTOMA DRUGS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF NEUROBLASTOMA DRUGS MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN NEUROBLASTOMA DRUGS MARKET (2022 TO 2032)
FIGURE 04. TOP INVESTMENT POCKETS IN NEUROBLASTOMA DRUGS MARKET (2023-2032)
FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
FIGURE 07. MODERATE THREAT OF SUBSTITUTES
FIGURE 08. MODERATE INTENSITY OF RIVALRY
FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
FIGURE 10. GLOBAL NEUROBLASTOMA DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF NEUROBLASTOMA DRUGS MARKET FOR CHEMOTHERAPY, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF NEUROBLASTOMA DRUGS MARKET FOR IMMUNOTHERAPY, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF NEUROBLASTOMA DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF NEUROBLASTOMA DRUGS MARKET FOR ORAL, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF NEUROBLASTOMA DRUGS MARKET FOR INJECTABLE, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF NEUROBLASTOMA DRUGS MARKET FOR ONLINE, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF NEUROBLASTOMA DRUGS MARKET FOR OFFLINE, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. NEUROBLASTOMA DRUGS MARKET BY REGION, 2022 AND 2032(%)
FIGURE 22. U.S. NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 23. CANADA NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 24. MEXICO NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 25. GERMANY NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 26. FRANCE NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 27. UK NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 28. ITALY NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 29. SPAIN NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 30. REST OF EUROPE NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 31. JAPAN NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 32. CHINA NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 33. INDIA NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 34. AUSTRALIA NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 35. SOUTH KOREA NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 36. REST OF ASIA-PACIFIC NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 37. BRAZIL NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 38. SAUDI ARABIA NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 39. SOUTH AFRICA NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 40. REST OF LAMEA NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 41. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 45. COMPETITIVE DASHBOARD
FIGURE 46. COMPETITIVE HEATMAP: NEUROBLASTOMA DRUGS MARKET
FIGURE 47. TOP PLAYER POSITIONING, 2022
FIGURE 48. RECORDATI GROUP: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 49. RECORDATI GROUP: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 50. RECORDATI GROUP: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 51. ASTRAZENECA PLC: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 52. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 53. BRISTOL-MYERS SQUIBB COMPANY: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 54. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 55. ELI LILLY AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 56. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 57. MACROGENICS INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 58. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 59. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 60. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 61. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 62. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 63. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 64. UNITED THERAPEUTICS CORPORATION: NET SALES, 2020-2022 ($MILLION)
FIGURE 65. UNITED THERAPEUTICS CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 66. Y-MABS THERAPEUTICS, INC.: NET REVENUE, 2020-2022 ($MILLION)

Product Code: A172697

The neuroblastoma drugs market was valued for $0.7 billion in 2022 and is estimated to reach $1.3 billion by 2032, exhibiting a CAGR of 6.2% from 2023 to 2032. Neuroblastoma is a type of cancer that primarily affects young children, typically arising in the adrenal glands, which are located on top of the kidneys. It is the most diagnosed disease in children under five, with most cases appearing in infants. This cancer originates from immature nerve cells, called neuroblasts, which are part of the sympathetic nervous system responsible for the "fight or flight" response.

Neuroblastoma varies widely in its behavior, ranging from spontaneous regression or maturation to aggressive, rapidly spreading forms. Symptoms of neuroblastoma can vary based on the location and size of the tumor but may include abdominal swelling, weight loss, irritability, fatigue, and changes in bowel habits. Neuroblastoma drugs are designed to target and inhibit the growth of cancerous neuroblastoma cells, either by directly attacking the cancer cells or by modulating the biological pathways involved in tumor development. The treatment approach for neuroblastoma often involves a combination of surgery, chemotherapy, radiation therapy, immunotherapy, and other targeted therapies.

The neuroblastoma drugs market is driven by a rise in incidences of neuroblastoma, advancements in R&D activities, and growth in awareness of neuroblastoma. The increasing incidences and prevalence of neuroblastoma, particularly among pediatric populations, is a pivotal factor driving the growth of the neuroblastoma drugs market. For instance, according to the National Center for Biotechnology and Information (NCBI) in 2023, the annual incidence of neuroblastoma in the U.S. was approximately 650 cases, i.e., 10.2 per million children. Thus, the growing prevalence of neuroblastoma led to an urgent need for effective and targeted drug therapies which contribute toward the market growth.

Consequently, pharmaceutical companies and research institutions are compelled to intensify their efforts in drug development, clinical trials, and collaborative research initiatives to address this rising health concern. The market's response to the increasing disease burden emphasizes the importance of advancing innovative treatments to improve outcomes and quality of life for individuals affected by neuroblastoma. In addition, the pharmaceutical industry has been witnessing significant investments in oncology research and drug development, thereby boosting the market growth. Neuroblastoma, as a subset of pediatric oncology, benefits from this broader trend, with increased funding and resources allocated to discovering and developing novel drugs. For instance, the National Cancer Institute (NCI) has made substantial investments in basic research, leading to the development of dinutuximab, a treatment for neuroblastoma.

However, the high cost of neuroblastoma treatment, and harmful side effects associated with neuroblastoma drugs are the factors responsible for the impeding the growth of the neuroblastoma drug market. In contrast, rise in number of pipeline drugs for neuroblastoma provides lucrative opportunity to the market growth. In addition, the exploration of combination therapies involving different classes of drugs, such as traditional chemotherapeutics, targeted agents, and immunotherapies, offers opportunities for enhanced treatment efficacy.

The neuroblastoma drugs market is segmented into type, route of administration, distribution channel, and region. By type, the market is classified into chemotherapy, immunotherapy, and others. By route of administration, the market is segregated into oral and injectable. By distribution channel, the market is classified into online and offline. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). Major key players that operate in the neuroblastoma drugs market are Recordati Group,, AstraZeneca plc, Bristol-Myers Squibb Company, Cellectar Biosciences, Inc., Eli Lilly and Company, MacroGenics Inc, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, and Y-mabs Therapeutics, Inc. Key players operating in the market have adopted agreement, acquisition, partnership, and product approval as their key strategies to expand their product portfolio.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the neuroblastoma drugs market analysis from 2022 to 2032 to identify the prevailing neuroblastoma drugs market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the neuroblastoma drugs market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global neuroblastoma drugs market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

Chemotherapy
Immunotherapy
Others

By Route of Administration

Oral
Injectable

By Distribution Channel

Online
Offline

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

AstraZeneca plc
Bristol-Myers Squibb Company
Cellectar Biosciences, Inc.
Eli Lilly and Company
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
United Therapeutics Corporation
Y-mabs Therapeutics, Inc.
Recordati Group
MacroGenics Inc.

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Moderate bargaining power of suppliers
- 3.3.2. Moderate threat of new entrants
- 3.3.3. Moderate threat of substitutes
- 3.3.4. Moderate intensity of rivalry
- 3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Rise in prevalence of neuroblastoma
  - 3.4.1.2. Growth in awareness & initiatives taken by the government for neuroblastoma
  - 3.4.1.3. Rise in R&D activities
- 3.4.2. Restraints
  - 3.4.2.1. Adverse effects and safety concerns
- 3.4.3. Opportunities
  - 3.4.3.1. Growth opportunities in emerging markets
  - 3.4.3.2. Rise in number of pipeline products

CHAPTER 4: NEUROBLASTOMA DRUGS MARKET, BY TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Chemotherapy
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Immunotherapy
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Others
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country

CHAPTER 5: NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Oral
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Injectable
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country

CHAPTER 6: NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Online
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Offline
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country

CHAPTER 7: NEUROBLASTOMA DRUGS MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Type
- 7.2.3. Market size and forecast, by Route of Administration
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Market size and forecast, by Type
  - 7.2.5.1.2. Market size and forecast, by Route of Administration
  - 7.2.5.1.3. Market size and forecast, by Distribution Channel
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Market size and forecast, by Type
  - 7.2.5.2.2. Market size and forecast, by Route of Administration
  - 7.2.5.2.3. Market size and forecast, by Distribution Channel
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Market size and forecast, by Type
  - 7.2.5.3.2. Market size and forecast, by Route of Administration
  - 7.2.5.3.3. Market size and forecast, by Distribution Channel
7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Type
- 7.3.3. Market size and forecast, by Route of Administration
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Market size and forecast, by Type
  - 7.3.5.1.2. Market size and forecast, by Route of Administration
  - 7.3.5.1.3. Market size and forecast, by Distribution Channel
  - 7.3.5.2. France
  - 7.3.5.2.1. Market size and forecast, by Type
  - 7.3.5.2.2. Market size and forecast, by Route of Administration
  - 7.3.5.2.3. Market size and forecast, by Distribution Channel
  - 7.3.5.3. UK
  - 7.3.5.3.1. Market size and forecast, by Type
  - 7.3.5.3.2. Market size and forecast, by Route of Administration
  - 7.3.5.3.3. Market size and forecast, by Distribution Channel
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Market size and forecast, by Type
  - 7.3.5.4.2. Market size and forecast, by Route of Administration
  - 7.3.5.4.3. Market size and forecast, by Distribution Channel
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Market size and forecast, by Type
  - 7.3.5.5.2. Market size and forecast, by Route of Administration
  - 7.3.5.5.3. Market size and forecast, by Distribution Channel
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Market size and forecast, by Type
  - 7.3.5.6.2. Market size and forecast, by Route of Administration
  - 7.3.5.6.3. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Type
- 7.4.3. Market size and forecast, by Route of Administration
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Market size and forecast, by Type
  - 7.4.5.1.2. Market size and forecast, by Route of Administration
  - 7.4.5.1.3. Market size and forecast, by Distribution Channel
  - 7.4.5.2. China
  - 7.4.5.2.1. Market size and forecast, by Type
  - 7.4.5.2.2. Market size and forecast, by Route of Administration
  - 7.4.5.2.3. Market size and forecast, by Distribution Channel
  - 7.4.5.3. India
  - 7.4.5.3.1. Market size and forecast, by Type
  - 7.4.5.3.2. Market size and forecast, by Route of Administration
  - 7.4.5.3.3. Market size and forecast, by Distribution Channel
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Market size and forecast, by Type
  - 7.4.5.4.2. Market size and forecast, by Route of Administration
  - 7.4.5.4.3. Market size and forecast, by Distribution Channel
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Market size and forecast, by Type
  - 7.4.5.5.2. Market size and forecast, by Route of Administration
  - 7.4.5.5.3. Market size and forecast, by Distribution Channel
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Market size and forecast, by Type
  - 7.4.5.6.2. Market size and forecast, by Route of Administration
  - 7.4.5.6.3. Market size and forecast, by Distribution Channel
7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Type
- 7.5.3. Market size and forecast, by Route of Administration
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Market size and forecast, by Type
  - 7.5.5.1.2. Market size and forecast, by Route of Administration
  - 7.5.5.1.3. Market size and forecast, by Distribution Channel
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Market size and forecast, by Type
  - 7.5.5.2.2. Market size and forecast, by Route of Administration
  - 7.5.5.2.3. Market size and forecast, by Distribution Channel
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Market size and forecast, by Type
  - 7.5.5.3.2. Market size and forecast, by Route of Administration
  - 7.5.5.3.3. Market size and forecast, by Distribution Channel
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Market size and forecast, by Type
  - 7.5.5.4.2. Market size and forecast, by Route of Administration
  - 7.5.5.4.3. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Recordati Group
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
9.2. AstraZeneca plc
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
9.3. Bristol-Myers Squibb Company
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
9.4. Cellectar Biosciences, Inc.
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
9.5. Eli Lilly and Company
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
9.6. MacroGenics Inc.
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
9.7. Pfizer Inc.
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
9.8. Teva Pharmaceutical Industries Ltd.
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
9.9. United Therapeutics Corporation
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
9.10. Y-mabs Therapeutics, Inc.
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments

神経芽細胞腫治療薬市場：タイプ別、投与経路別、流通チャネル別：世界の機会分析と産業予測、2023-2032年

Neuroblastoma Drugs Market By Type (Chemotherapy, Immunotherapy, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Online, Offline): Global Opportunity Analysis and Industry Forecast, 2023-2032

利害関係者にとっての主なメリット

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章神経芽細胞腫治療薬市場：タイプ別

第5章神経芽細胞腫治療薬市場：投与経路別

第6章神経芽細胞腫治療薬市場：流通チャネル別

第7章神経芽細胞腫治療薬市場：地域別

第8章競争情勢

第9章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Type

By Route of Administration

By Distribution Channel

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: NEUROBLASTOMA DRUGS MARKET, BY TYPE

CHAPTER 5: NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION

CHAPTER 6: NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: NEUROBLASTOMA DRUGS MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

神経芽細胞腫治療薬市場：タイプ別、投与経路別、流通チャネル別：世界の機会分析と産業予測、2023-2032年

Neuroblastoma Drugs Market By Type (Chemotherapy, Immunotherapy, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Online, Offline): Global Opportunity Analysis and Industry Forecast, 2023-2032

利害関係者にとっての主なメリット

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

第4章 神経芽細胞腫治療薬市場：タイプ別

第5章 神経芽細胞腫治療薬市場：投与経路別

第6章 神経芽細胞腫治療薬市場：流通チャネル別

第7章 神経芽細胞腫治療薬市場：地域別

第8章 競争情勢

第9章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Type

By Route of Administration

By Distribution Channel

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: NEUROBLASTOMA DRUGS MARKET, BY TYPE

CHAPTER 5: NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION

CHAPTER 6: NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: NEUROBLASTOMA DRUGS MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章神経芽細胞腫治療薬市場：タイプ別

第5章神経芽細胞腫治療薬市場：投与経路別

第6章神経芽細胞腫治療薬市場：流通チャネル別

第7章神経芽細胞腫治療薬市場：地域別

第8章競争情勢

第9章企業プロファイル